Asceneuron SA today announces the publication of peer-reviewed data in the journal ACS Chemical Neuroscience regarding ASN90, an O–GlcNAcase (OGA) inhibitor, and one of its leading candidates in clinical development for treating neurodegenerative proteinopathies. Neurodegenerative proteinopathies such as Alzheimer’s and Parkinson’s disease are characterized by the intracellular formation in the brain of insoluble and toxic…

eTurboNews amanqaku ngababhalisi kuphela. Umrhumo ngu fREE.
Ababhalisi bangena apha Cofa apha ukuze ubhalise FREE

INTO ONOKUYITHATHA KWELI NQAKU:

I-Asceneuron SA namhlanje ibhengeza ukupapashwa kwedatha ephononongwe ngontanga kwijenali ye-ACS Chemical Neuroscience malunga ne-ASN90, i-O-GlcNAcase (OGA) inhibitor, kunye nomnye wabaviwa bayo abakhokelayo kuphuhliso lwezonyango lokunyanga i-neurodegenerative proteinopathies.
Neurodegenerative proteinopathies such as Alzheimer’s and Parkinson’s disease are characterized by the intracellular formation in the brain of insoluble and toxic….
eTurboNews amanqaku ngababhalisi kuphela.